2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1379

Differential Effects Of TNF Inhibitors, Anti-IL-6 Receptor Antibody and CTLA4-Ig On Human Monocytes
Abstract Number: 565

Differential Efficacy Of Human Mesenchymal Stem Cells On Disease In Murine Lupus Based On Source Of Origin
Abstract Number: 1623

Differential Methylation Of Interferon-Related Genes Is Associated With Anti-dsDNA Autoantibody Production In Systemic Lupus Erythematosus
Abstract Number: 1886

Differential Methylation Related To Response To Etanercept In Patients With Rheumatoid Arthritis
Abstract Number: 1150

Differential Regulation Of IL-10 and Dusp1 Production By Kinases In The p38 MAPK Pathway
Abstract Number: 28

Differentiation, Activation, and Autoreactivity Of CD11c+ B Cells (ABCs)
Abstract Number: 110

Differing Disease Expression In Latin American Mestizo and Spanish Caucasian Patients With Rheumatoid Arthritis With The Same Access To Healthcare and Antirheumatic Treatment
Abstract Number: 213

Digital Tomosynthesis for Measurement of Bone Erosion in Gout: Comparison With Computed Tomography
Abstract Number: 1400

Dipeptidyl Peptidase IV (DPP-IV, CD26) Levels In Patients With Rheumatoid Arthritis Treated With Biologic Therapies and Correlation With The Activity Of The Disease
Abstract Number: 2658

Dipeptidyl Peptidase-4 Inhibitors In Type 2 Diabetes May Reduce The Risk Of Autoimmune Diseases
Abstract Number: 1769

Direct and Indirect Costs For Patients With Systemic Lupus Erythematosus In National Cohorts In Sweden
Abstract Number: 124

Disability In Fibromyalgia Is Associated With Greater Self-Reported Symptoms and Functional Impairment
Abstract Number: 2367

Discontinuation Of Biological Therapy Due To Adverse Drug Reactions In Rheumatoid Arthritis Patients: 12 Years Follow-Up
Abstract Number: 1425

Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits
Abstract Number: 1055

Discontinuation Rates In Patients With RA Of Triple Disease Modifying Antirheumatic Therapy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].